Merck & Co., Inc. Equity Securities, FV-NI, Realized Gain (Loss)
Merck & Co., Inc. (MRK) reported Equity Securities, FV-NI, Realized Gain (Loss) of -$1.00 billion for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-24.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2023-02-24
- Merck & Co., Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2022 was -$1.00B, a 171.43% decline from fiscal 2021.
- Merck & Co., Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2021 was $1.40B, a 140.14% increase from fiscal 2020.
- Merck & Co., Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2020 was $583.00M.
- Merck & Co., Inc. equity securities, fv-ni, realized gain (loss) for fiscal 2019 was -$113.00M.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 12 month |
|---|---|
| 2022-12-31 | -$1.00B 10-K · filed 2023-02-24 |
| 2021-12-31 | $1.40B 10-K · filed 2023-02-24 |
| 2020-12-31 | $583.00M 10-K · filed 2023-02-24 |
| 2019-12-31 | -$113.00M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |